3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Glioblastoma
3
Glioma
2
Uveal Melanoma
1
Recurrence
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Interventions
Cyclophosphamide
2
pembrolizumab
1
molibresib
1
fludarabine phosphate
1
fludarabine
1
etoposide phosphate
1
Temozolomide
1
Sirolimus
1
Pemetrexed
1
Oncolytic Virotherapy
1
Mesna
1
Etoposide
1
Craniotomy
1
Celecoxib
1
Carboplatin
1
ADI PEG20
1
3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione
1
1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
ADI PEG20
×
CNS
×
Clear all
NCT02029690
2020-09-25
TRAP
Polaris Group
Phase 1
Terminated
85 enrolled